Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accounts Payables (2016 - 2026)

Corvus Pharmaceuticals' Accounts Payables history spans 12 years, with the latest figure at $4.7 million for Q1 2026.

  • Quarterly Accounts Payables rose 987.27% to $4.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Mar 2026, up 987.27% year-over-year, with the annual reading at $2.5 million for FY2025, 3.52% down from the prior year.
  • Accounts Payables came in at $4.7 million for Q1 2026, up from $2.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.7 million in Q1 2026 to a low of $432000.0 in Q1 2025.
  • The 5-year median for Accounts Payables is $2.0 million (2022), against an average of $2.2 million.
  • Year-over-year, Accounts Payables crashed 73.15% in 2025 and then surged 987.27% in 2026.
  • Corvus Pharmaceuticals' Accounts Payables stood at $2.0 million in 2022, then fell by 22.82% to $1.5 million in 2023, then skyrocketed by 69.31% to $2.6 million in 2024, then fell by 3.52% to $2.5 million in 2025, then soared by 88.56% to $4.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Accounts Payables are $4.7 million (Q1 2026), $2.5 million (Q4 2025), and $1.2 million (Q3 2025).